Sandoz To Acquire Oriel Therapeutics, Gaining Rights To Portfolio Of Respiratory Products Targeting Asthma And COPD
Sandoz has signed a definitive agreement to acquire Oriel Therapeutics, a privately held US pharmaceuticals company, gaining exclusive rights to a portfolio of generic drug candidates and related technologies targeting medicines in the inhalable respiratory drug market. Terms of the deal were not disclosed.

Read more on PharmaceuticalOnline